Pancreatic Cancer Research

ResearcherDalian Medical UniversityNo recent work listed

Aman Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8810-3711; OpenAlex author ID A5048428790. Sources: OpenAlex.

Their work

Papers
8 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2014: 4 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper

Papers 8

  1. RIOK3 promotes mTORC1 activation by facilitating SLC7A2-mediated arginine uptake in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/aging.204528↗
  2. RIOK3 promotes pancreatic ductal adenocarcinoma cell invasion and metastasis by stabilizing FAK. Last author DOI 10.1016/j.heliyon.2022.e10116↗
  3. Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer. Co-author DOI 10.3389/fonc.2022.991051↗
  4. [Corrigendum] USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β‑catenin nuclear localization and is associated with poor prognosi… First author DOI 10.3892/ijo.2019.4871↗
  5. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II … First author DOI 10.3892/ijo.2014.2531↗
  6. USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells. First author DOI 10.3892/or.2014.3354↗
  7. Ubiquitin‑specific protease 22‑induced autophagy is correlated with poor prognosis of pancreatic cancer. Co-author DOI 10.3892/or.2014.3508↗
  8. Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis. First author PMID 24966957↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhen Ning · 7 shared papers, 2014–2023 · strength 0.64
  2. Henan Qin · 3 shared papers, 2022–2023 · strength 0.50
  3. Jiwei Liu · 4 shared papers, 2014–2023 · strength 0.43
  4. Mengyuan Xu · 2 shared papers, 2022–2023 · strength 0.36
  5. Zhongyu Wang · 3 shared papers, 2014–2019 · strength 0.20
  6. Chang Liu · 1 shared paper, 2022 · strength 0.15
  7. Haihua Liu · 1 shared paper, 2022 · strength 0.15
  8. Dong Shang · 1 shared paper, 2022 · strength 0.15
  9. Peiyuan Yin · 1 shared paper, 2022 · strength 0.15
  10. Zhongyu Wang · 1 shared paper, 2014 · strength 0.04
  11. Jinxiao Liang · 1 shared paper, 2014 · strength 0.04
  12. Zhongyu Wang · 1 shared paper, 2014 · strength 0.04
  13. Haifeng Luo · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.